Company intelligence / Profile preview
Shanghai Reinovax Biologics Co., Ltd.
Shanghai, Shanghai, Chinareinovaxbio.com ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company's lead product, a 24-valent pneumococcal polysaccharide conjugate vaccine (PCV-24), has completed Phase I trials and is currently in Phase II clinical trials for pneumococcal infections in China. Phase I was completed on November 15, 2024, and Phase II trials began on April 20, 2024, targeting adults and the elderly.
- Therapeutic areas
- PulmonologyInfectious Diseases
- Modalities
- VaccinesConjugate vaccinesPolysaccharide vaccinesmRNA
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Beyond the preview
Go deeper on Shanghai Reinovax Biologics Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Shanghai Reinovax Biologics Co., Ltd..